Nycomed snags Bruker contrast injector
The increasing speed of MRI and CT systems and their expanding vascular indications have made precision and reproducibility paramount considerations in contrast-enhanced studies. In mid-January, Nycomed Amersham locked in access to this technology,
The increasing speed of MRI and CT systems and their expanding vascular indications have made precision and reproducibility paramount considerations in contrast-enhanced studies. In mid-January, Nycomed Amersham locked in access to this technology, acquiring a sophisticated power injector system from Swiss-based manufacturer Bruker. Called Tomoject, this pump injector provides the constant and reliable flow of contrast media necessary for ultrafast imaging, including contrast-enhanced angiography, tumor diagnostics, organ perfusion, and incremental body imaging. Tomoject is currently marketed in Europe and other international venues. The manufacturing site will remain Zurich.
ASCO: Study Reveals Significant Racial/Ethnic Disparities with PSMA PET Use for Patients with mPCa
May 30th 2025Latinx patients with metastatic prostate cancer were 63 percent less likely than non-Hispanic White patients to have PSMA PET scans, according to a study of 550 patients presented at the American Society of Clinical Oncology (ASCO) conference.
Lunit Unveils Enhanced AI-Powered CXR Software Update
May 28th 2025The Lunit Insight CXR4 update reportedly offers new features such as current-prior comparison of chest X-rays (CXRs), acute bone fracture detection and a 99.5 percent negative predictive value (NPV) for identifying normal CXRs.
New MRI Study Questions Use of Corticosteroid Injections for Knee OA
May 27th 2025Two years after intraarticular knee injections for knee osteoarthritis (OA), study participants who had corticosteroid knee injections had greater OA progression than control patients while the use of hyaluronic acid injections was associated with less OA progression.
